5 results
To test the impact of the addition of axitinib to standard chemotherapy treatment on histology samples
Safety objective: To evaluate the safety and tolerability of UTTR1147AExploratory Efficacy Objective: To evaluate the efficacy of UTTR1147AExploratory Pharmacokinetic Objective: To evaluate potential relationships between long-term drug exposure and…
Primary: Evaluate the efficacy of patient-derived tumor organoids to successfully allocate patients for treatment with specific targeted agents.Secondary: Characterize safety and tolerability per experimental treatment regimen.
This study will evaluate the safety, efficacy, and pharmacokinetics of UTTR1147A compared with placebo and compared with vedolizumab in patients with moderate to severe ulcerative colitis (UC).
To compare the 120 mg once daily (QD) dose and 200 mg QD dose of MK*6482with respect to objective response rate (ORR) based on Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR).